After detecting MED13L expression in biopsy of 108 stage III NSCLC patients treated with concurrent chemoradiotherapy (Jiangsu cohort), we found that NSCLC patients with a relatively high MED13L expression exhibited significantly shorter survival time (PFS and OS) compared to cases with low MED13L expression (both Logrank P ≤ 0.001) (Figure 3B). Here, MED13L is linked to non-small cell lung carcinoma.